Date: Tuesday, August 17, 2021
Time: 2:00 pm - 3:00 pm (ET)
A few minutes before the webinar starts,
please click on the Zoom link below to join:
Or One tap mobile:
US:+16692545252,,1602130331#,,,,*549822#
or +16468287666,,1602130331#,,,,*549822#
Or Telephone:
US: +1 669 254 5252 or
+1 646 828 7666 or
+1 669 216 1590 or
+1 551 285 1373
Webinar ID: 160 213 0331
Passcode: 549822
International numbers available: https://www.zoomgov.com/u/acYoOcgd4E
The U.S. Food and Drug Administration (FDA) has issued Emergency Use Authorizations (EUA) for additional doses of mRNA COVID-19 vaccines for moderately to severely immunocompromised people. People with immunocompromising conditions or who take immunosuppressive medications or therapies are at increased risk for severe COVID-19. Studies indicate that some immunocompromised people have a reduced immune response following a primary COVID-19 vaccine series compared to vaccine recipients who are not immunocompromised. Studies have further demonstrated that an additional mRNA COVID-19 vaccine dose after an initial 2-dose primary mRNA COVID-19 vaccine series in some immunocompromised populations may enhance immune response.
During this COCA Call, presenters will discuss the current data on COVID-19 vaccines in immunocompromised people; the role of additional doses of mRNA COVID-19 vaccines, patients who should be considered to receive these additional COVID-19 vaccine doses, results from the August 13, 2021, Advisory Committee on Immunization Practices (ACIP) meeting, and CDC’s guidance on additional COVID-19 doses in immunocompromised people.
If you are unable to attend the live COCA Call, the recording will be available for viewing on the COCA Call webpage a few hours after the live event ends.
The slide set will be available under "Call Materials" on the COCA Call webpage.
Registration is not required.